Eagle's Eye View: Your Weekly CV Update From ACC.org

In this week’s View, Dr. Eagle looks at the 2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis. He then discusses sex differences in patients undergoing FFR-guided PCI or CABG in the FAME 3 Trial. Finally, Dr. Eagle explores long-term management of right ventricular outflow tract (RVOT) dysfunction in repaired tetralogy of Fallot (TOF).  Subscribe to Eagle’s Eye View    

In this week’s View, Dr. Eagle looks at the use of waist-high compression tights in patients with postural orthostatic tachycardia syndrome (POTS). He then discusses a consensus statement on platelet function and genetic testing in percutaneous coronary intervention (PCI). Finally, Dr. Eagle explores aspirin monotherapy versus no antiplatelet therapy in stable patients with coronary stents undergoing low-to-intermediate-risk noncardiac surgery.   Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at the prevalence of overweight and obesity among children, adolescents, and adults in the U.S., with forecasts up to 2050. He then discusses consensus recommendations on cardiopulmonary resuscitation (CPR). Finally, Dr. Eagle explores bleeding risk using nonsteroidal anti-inflammatory drugs (NSAIDs) with anticoagulants after venous thromboembolism.    Subscribe to Eagle’s Eye View  

In this special edition of Eagle’s Eye View, Dr. Eagle looks at the most important trials presented at the recent AHA scientific sessions: 1) BROAD, exploring more intensive blood pressure control; 2) SUMMIT, evaluating tirzepatide use in obesity-related HFpEF in people with diabetes; 3) OPTION, comparing left atrial appendage closure to oral anticoagulation therapy for stroke protection in post-ablation patients with atrial fibrillation; 4) CLEAR SYNERGY, dual trials on the use of spironolactone vs. placebo and colchicine vs. placebo in patients with myocardial infarction, and 5) Project My Heart Your Heart, developing a protocol of the use of refurbished pacemakers.    Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at exercise training in patients with hypertrophic cardiomyopathy (HCM). He then reviews the diagnosis and management of Kawasaki Disease. Finally, Dr. Eagle discusses the association of self-reported race, social determinants of health (SDoH), and polygenic risk for coronary heart disease (CHD).    Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at contemporary outcomes and trends for the transseptal mitral valve-in-valve procedure using balloon-expandable transcatheter valves. He then explores complete vs. culprit-only revascularization in older patients with myocardial infarction (MI) with or without ST-segment elevation. Finally, Dr. Eagle discusses hypertensive disorders of pregnancy and whether they increase the risk for MI.    Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at the outcomes of balloon-expandable transcatheter aortic valve replacement (TAVR) in younger patients. He then explores the comparative effectiveness and safety of atorvastatin versus rosuvastatin. Finally, Dr. Eagle discusses the results of the RESET-BP randomized trial that studied the effects of sedentary behavior’s reduction of blood pressure in desk workers.     Subscribe to Eagle’s Eye View  

In this special edition of Eagle’s Eye View, Dr. Eagle looks four of the most important trials presented at the recent TCT Conference: 1) EARLY TAVR evaluating TAVR compared to clinical surveillance; 2) TRISCEND II looking at the Evoque transcatheter tricuspid valve replacement (TTVR) system for severe tricuspid regurgitation; 3) ECLIPSE evaluating orbital atherectomy prior to drug-eluting stent implant compared to conventional PCI; and 4) CLEAR SYNERGY (OASIS 9) assessing the effects of colchicine after PCI for a STEMI or large NSTEMI.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at the consequences of discontinuing long-term drug treatment in patients with heart failure and reduced ejection fraction (HFrEF). He then explores the effect of race and sacubitril/valsartan use in HF patients documented in a pooled analysis of the PARADIGM-HF and PARAGON-HF trials. Finally, Dr. Eagle discusses the utility of systolic blood pressure (BP) polygenic risk scores and the treatment response in people with hypertension.    Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at anthracycline cardiotoxicity in treatment of cancer patients. He then explores a scientific statement from the American Heart Association on cardiac arrhythmias and autonomic dysfunction associated with COVID-19. Finally, Dr. Eagle discusses the SWEDEHEART registry and intensive early and sustained lowering of non–HDL cholesterol after MI and prognosis.    Subscribe to Eagle’s Eye View